Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 19400 pfu - injection, powder for - excipient ingredients: monosodium glutamate monohydrate; monobasic potassium phosphate; urea; sodium chloride; dibasic sodium phosphate; hydrolysed gelatin; potassium chloride; sucrose - zostavax is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older. zostavax is indicated for the prevention of postherpetic neuralgia (phn) and for reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older.

Malta - English - Medicines Authority

ferring pharmaceuticals limited drayton hall, church road, west drayton ub7 7ps, united kingdom - chorionic gonadotrophin, human - powder and solvent for solution for injection - chorionic gonadotrophin, human 1500 iu - sex hormones and modulators of the genital system

Malta - English - Medicines Authority

ferring pharmaceuticals limited drayton hall, church road, west drayton ub7 7ps, united kingdom - chorionic gonadotrophin, human - powder and solvent for solution for injection - chorionic gonadotrophin, human 5000 iu - sex hormones and modulators of the genital system

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: mannitol; polylactic acid - in the palliative treatment of metastatic or locally extensive prostate cancer (stage c and d).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - leuprorelin acetate 3.75mg (powder for injection compartment) - injection (depot) - 3.75 mg - active: leuprorelin acetate 3.75mg (powder for injection compartment) excipient: acetic acid carmellose sodium gelatin plga (copoly (dl-lactic acid/glycolic acid) 75:25mol%) powder for injection compartment mannitol polysorbate 80 water for injection - lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - leuprorelin acetate 30mg (powder for injection compartment) - injection (depot) - 30 mg - active: leuprorelin acetate 30mg (powder for injection compartment) excipient: carmellose sodium glacial acetic acid lactic acid mannitol polysorbate 80 water for injection - lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - omalizumab, quantity: 75 mg - injection, solution - excipient ingredients: water for injections - allergic asthma,children 6 to < 12 years of age - in children aged 6 to <12 years, xolair is indicated as add-on therapy to improve asthma control in patients with severe allergic asthma who have documented exacerbations despite daily high dose inhaled corticosteroids, and who have immunoglobulin e levels corresponding to the recommended dose range (see table 1 in section 4.2 dose and method of administration).,adults and adolescents 12 years of age and above -xolair is indicated for the management of adult and adolescent patients with moderate to severe allergic asthma, who are already being treated with inhaled steroids, and who have serum immunoglobulin e levels corresponding to the recommended dose range (see table 1 in section 4.2 dose and method of administration).,chronic rhinosinusitis with nasal polyps (crswnp),xolair is indicated as add-on treatment in adult patients (18 years of age and above) for the treatment of severe crswnp with inadequate response to intranasal corticosteroids. recommended dosing is determined by serum immunoglobulin e levels and body weight corresponding to the recommended dose range in the product information (see section 4.2 dose and method of administration).,chronic spontaneous urticaria (csu),xolair is indicated for adults and adolescents (12 years of age and above) with chronic spontaneous urticaria who remain symptomatic despite h1 antihistamine treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - lutropin alfa, quantity: 75 iu - injection, powder for - excipient ingredients: methionine; sodium hydroxide; phosphoric acid; sucrose; polysorbate 20; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate - luveris in association with a recombinant follicle stimulating hormone (fsh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials, these patients were defined by an endogenous serum lh of less than 1.2 iu/l.

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - chorionic gonadotrophin - powder and solvent for solution for injection - 1500 international unit(s) - chorionic gonadotrophin - cattle, dogs, horses - hormone

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone mesilate, quantity: 27.29 mg (equivalent: ziprasidone, qty 20 mg) - injection, powder for - excipient ingredients: sulfobutyl betadex sodium - acute control and short-term management of agitation and disturbed behaviours in patients with schizophrenia and related psychoses when oral therapy is not appropriate.